Remove Capital Market Remove Medical Remove Private Equity
article thumbnail

What is the Value of my Medical Practice?

Focus Investment Banking

This article focuses on how medical practices are valued by private equity-backed groups, and to an extent, health systems and other strategic acquirers. Physician practices are almost always valued on a multiple of EBITDA basis in transactions with private equity groups or similar buyers.

Medical 52
article thumbnail

A Lookback: Tyton Partners Last 50 Transactions + Key Deal Takeaways

Tyton Partners

Excolere Equity Partners is a leading middle market private equity firm that leverages its deep sector experience and strategic and operational expertise to accelerate the growth and enhance the impact of companies in the Education and Human Capital sector.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Periculum Advises Micro-Dyn Systems in its Sale to The Brydon Group

Periculum Capital

Periculum Capital Company, LLC is pleased to announce it has advised Micro-Dyn Medical Systems, Inc., based private equity investor that specializes in acquiring software businesses in partnership with top mid-career executives. a leading health care software company, in its acquisition by The Brydon Group.

Sale 52
article thumbnail

2024 Key Deal Highlights and Predictions for 2025

Tyton Partners

K-12 Transaction Spotlight The K-12 education market is undergoing a significant transformation in the post-COVID era, driven by the expiration of federal Elementary and Secondary School Emergency Relief (ESSER) funds.

article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers.

M&A 52
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. The strong capital markets environment that has prevailed during the past few years has enabled a large number of development-stage and one?product,

M&A 40